Please use this identifier to cite or link to this item:
Title: High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience
Author: Rodríguez García, José A.
Caballero García, María Dolores
Gutiérrez, Antonio
Gandarillas, Marco
Sierra Gil, Jorge
López Guillermo, Armando
Zuazu, Javier
Marín Solano, Jesús
Arranz, Reyes
Carreras Gómez, Enric
León, Ángel
Fernández de Sevilla Ribosa, Alberto
San Miguel, Jesús F.
Conde, Eulogio
GEL/TAMO Spanish Group
Keywords: Ús terapèutic
Cèl·lules T
Cèl·lules mare
Therapeutic use
T cells
Stem cells
Issue Date: 1-Dec-2003
Publisher: Ferrata Storti Foundation
Abstract: Background and objectives: patients with aggressive non-Hodgkin's lymphomas (NHL) who do not obtain a complete response (CR) after induction chemotherapy have a poor prognosis. However, provided they are sensitive to the first regimen of chemotherapy, 25-40% of them with a B-cell phenotype may achieve long-term survival when treated with high dose chemotherapy and autologous stem cell transplantation (HDC/ASCT). The aim of this study was to analyze the efficacy of this therapy in the corresponding patients with peripheral T-cell lymphoma (PTCL). Design and methods: we retrospectively evaluated the efficacy of ASCT in 35 patients with PTCL from the GEL-TAMO registry, who did not achieve a CR to standard induction chemotherapy regimens for aggressive NHL. Thirty-one patients underwent transplantation after achieving a partial response (PR) and 4 patients were non-responders. Results: following HDC/ASCT, 23 (66%) of the patients achieved a CR, 4 (11%) a PR and in 7 (20%) cases the transplant failed. One patient was not evaluated because of early toxic death. With a median follow-up of the survivors of 37.5 months, 18 patients (51%) are alive and 15 patients (43%) are free of disease. Transplant-related mortality rate at 100 days was 11% and at 5 years the probabilities of survival, freedom from progression and disease-free survival for complete responders were 37%, 36% and 55% respectively. Pre-transplant lactate-dehydrogenase level, age-adjusted International Prognostic Index (aa-IPI) and tumor score correlated with survival. Interpretation and conclusions: one third of the patients with PTCL who fail to achieve CR to the first chemotherapeutic regimen can be rescued with HDC/ASCT. Pre-transplant values of IPI and tumor score risk systems for aggressive lymphomas were useful to predict subsequent survival.
Note: Reproducció del document publicat a:
It is part of: Haematologica, 2003, vol. 88, num. 12, p. 1372-1377
ISSN: 0390-6078
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
519009.pdf108.75 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.